Rallis India Q1 revenue rises 6.8%, but Nuvama keeps Reduce with ₹216 target
Rallis India reported Q1 FY27 revenue of ₹1,020 crore, supported by 15% growth in domestic formulations volume. Nuvama retained its Reduce call, flagging weak sowing, potential Q2 sales returns and pressure on export active-ingredient pricing.
What happened
Tata Group agro-sciences company Rallis India posted Q1 FY27 revenue growth above expectations, helped by domestic formulations volumes. Nuvama retained its
Key facts
- Revenue rose 6.8% YoY to Rs 1,020 crore
- Domestic formulations volume grew 15%
- One-time employee-cost reversal: Rs 35 crore
- Nuvama target price: Rs 216
- CMP: Rs 227.50
- FY28E valuation: 15x EPS; CMP at 17.3x FY28E EPS
- Promoter Tata Chemicals stake: 55.04%
- 5-year PAT CAGR: -2%
- FY26-FY28E PAT CAGR assumption: 16%
- FY28E RoE: 11.8%
Why this matters
The domestic formulations momentum highlights an attractive growth engine, though exposure to volatile export active-ingredient pricing and seasonal sowing conditions remains a strategic constraint.
What to watch
- Kharif sowing acreage materially below normal levels in major crop regions
- Delayed or uneven monsoon rainfall during the peak application window
- Higher-than-expected Q2 dealer returns or inventory write-downs
- Domestic formulations volume growth falling below low-double-digit levels
- Further decline in export active-ingredient prices or lower export order intake
- Gross-margin contraction despite revenue growth
- Increase in receivable days or weaker operating cash conversion
- Track July-August sowing acreage, rainfall distribution and pest-incidence data for evidence of in-season agrochemical demand.
- Monitor management commentary on channel inventory, Q2 sales-return provisions and receivable days.
- Watch domestic formulations price discipline versus volume growth; aggressive discounting would weaken the quality of revenue growth.
- Assess export active-ingredient realizations, order visibility and Chinese supply-driven pricing trends.
- Expect broker estimate revisions to focus more on FY27 margin and cash-flow assumptions than on Q1 revenue growth.